Deferasirox Efficacy and Safety for the Treatment of Transfusion-Dependent Iron Overload in Patients with a Range of Rare Anemias.

被引：0
|
作者：
Porter, John B. [1 ]
Lin, Kai-Hsin [2 ]
Habr, Dany [3 ]
Domokos, Gabor [4 ]
Hmissi, Abdel [4 ]
Thein, Swee Lay [5 ]
机构：
[1] UCL, London, England
[2] Natl Taiwan Univ Hosp, Taipei, Taiwan
[3] Novartis, E Hanover, NJ USA
[4] Novartis, Basel, Switzerland
[5] Kings Coll Hosp London, London, England
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：506 / 506
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety of Deferasirox (Exjade®) in Patients with Transfusion-Dependent Anemias: 1-Year Results from the Large, Prospective, Multicenter EPIC Study
    Cappellini, Maria Domenica
    El-Beshlawy, Amal
    Kattamis, Antonis
    Lee, Jong Wook
    Seymour, John F.
    Li, Chi-Kong
    Habr, Dany
    Domokos, Gabor
    Hmissi, Abdel
    Elafy, Mohsen Saleh
    [J]. BLOOD, 2008, 112 (11) : 1319 - 1319
  • [22] Iron overload in transfusion-dependent thalassemia
    Saliba, Antoine
    Taher, Ali
    [J]. HEMATOLOGY, 2015, 20 (05) : 311 - 312
  • [23] Pharmacokinetics, Metabolism, and Disposition of Deferasirox in β-Thalassemic Patients with Transfusion-Dependent Iron Overload Who Are at Pharmacokinetic Steady State
    Waldmeier, Felix
    Bruin, Gerard J.
    Glaenzel, Ulrike
    Hazell, Katharine
    Sechaud, Romain
    Warrington, Steve
    Porter, John B.
    [J]. DRUG METABOLISM AND DISPOSITION, 2010, 38 (05) : 808 - 816
  • [24] A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan
    Ho, Wan-Ling
    Chung, Kuo-Piao
    Yang, Szu-Sheng
    Lu, Meng-Yao
    Jou, Shiann-Tarng
    Chang, Hsiu-Hao
    Yang, Yung-Li
    Lin, Dong-Tsamn
    Lin, Kai-Hsin
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2013, 112 (04) : 221 - 229
  • [25] Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia
    Taher, Ali T.
    Temraz, Sally
    Cappellini, M. Domenica
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (05) : 495 - 509
  • [26] Geographical Differences In Transfusion and Iron Chelation Practices In 1558 Patients with Transfusion-Dependent Anemias
    Viprakasit, Vip
    Gattermann, Norbert
    Lee, Jong Wook
    Porter, John B.
    Taher, Ali
    Habr, Dany
    Roubert, Bernard
    Domokos, Gabor
    Cappellini, Maria Domenica
    [J]. BLOOD, 2010, 116 (21) : 1733 - 1734
  • [27] DEFERASIROX EFFICACY IS INDIPENDENT BY IMPROVEMENT OF IRON OVERLOAD BIOCHEMICAL MARKERS IN TRANSFUSION DEPENDENT MYELODYSPLASTIC PATIENTS
    Volpe, M.
    Volpe, A.
    [J]. HAEMATOLOGICA, 2012, 97 : 708 - 708
  • [28] Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes
    Roy, Noemi B. A.
    Myerson, Saul
    Schuh, Anna H.
    Bignell, Patricia
    Patel, Roger
    Wainscoat, Jim S.
    McGowan, Simon
    Marchi, Emanuele
    Atoyebi, Wale
    Littlewood, Tim
    Chacko, Joseph
    Vyas, Paresh
    Killick, Sally B.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2011, 154 (04) : 521 - 524
  • [29] IRON CHELATION THERAPY IN MYELODYSPLASTIC SYNDROMES AND IN OTHER TRANSFUSION-DEPENDENT CHRONIC ANEMIAS. RETROSPECTIVE STUDY OF 69 PATIENTS FROM A SINGLE INSTITUTION
    Finelli, C.
    Clissa, C.
    Barraco, M.
    De Maio, C.
    Stanzani, M.
    Parisi, S.
    Paolini, S.
    Bosi, C.
    Cavo, M.
    [J]. HAEMATOLOGICA, 2017, 102 : 770 - 771
  • [30] Safety and efficacy of deferasirox in the management of transfusion-dependent patients with myelodysplastic syndrome and aplastic anaemia: a perspective review
    Adams, Rebecca L. C.
    Bird, Robert J.
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2013, 4 (02) : 93 - 102
12345